The world of pharmaceutical development is changing, and so are we.
As technologies evolve, the development of novel therapeutics is changing, growing from an industry solely focused on medicinal chemistry – the development of small molecules for the treatment of disease – to one that is discovering and developing a much wider range of therapies.
At MedChemNet, we recognize the importance to keep up with the ever-changing industry. In light of this, we will be expanding the focus of the site to cover the entire drug discovery and development pipeline – from target to candidate, and beyond. As well as continuing to provide you with the latest news, views and opinion from key leaders in the field, we are changing our name to RxNet.
Our new name will reflect the broad and exciting range of content we publish, from target identification through to first-in-human clinic trials and from classic small molecule therapeutics to biologics, large molecules and novel drug delivery systems. We look forward to sharing many more insightful features throughout the coming months.
Our Spotlights and other features will continue to address hot topics in the industry, drawing on expert opinions from researchers at various stages of development. Over the past 2 months, we have been exploring the use of computational chemistry in drug discovery and the rise of artificial intelligence. Look out for more special features over the coming months and years.
We’ve had a huge year, and we’re not slowing down. There is a lot happening on the new RxNet and we’re very excited to be making this change. I look forward to sharing our new, broader range of content with you in the coming months.
Additionally, if you would like to share your research with other members of the RxNet community, we’d be delighted to hear from you. You can reach us at email@example.com – we look forward to hearing from you.
My very best wishes,